PBSV supply chain intelligence for Pharma-Bio Serv, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Pharma-Bio Serv, Inc. (PBSV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GLOBAL-GROUPS-OF-AFFILIATED-COMPANIES | GLOBAL-GROUPS-OF-AFFILIATED-COMPANIES | 92% | During the three months ended January 31, 2026, aggregate revenues from these global groups of affiliated companies were 16.1 %, 15.5 %, 15.0 % and 0.0 %, or a total of 46.6 % |
| THREE-GROUPS-OF-AFFILIATED-COMPANIES | THREE-GROUPS-OF-AFFILIATED-COMPANIES | 92% | At the global level three groups of affiliated companies accounted for 10% or more of our revenues in either October 31, 2024 or 2023. |
| PHARMA-BIO-SERV-PR-INC | PHARMA-BIO-SERV-PR-INC | 62% | 1 Depreciation and amortization 14,796 9,439 Amortization of operating lease right-of-use 29,388 41,386 Reinvested interests ( 83,346 ) ( 137,759 ) Increase in accounts receivable ( 277,116 ) ( 186,3… |
| PHARMA-BIO-SERV-PR-INC-PHARMA-SERV-INC | PHARMA-BIO-SERV-PR-INC-PHARMA-SERV-INC | 62% | . For the three months ended January 31, 2026 and 2025, net income and net earnings per common share (both basic and diluted) were approximately breakeven. 15 Table of Contents Liquidity and Capital … |
| PHARMA-BIO-SERV-US-INC | PHARMA-BIO-SERV-US-INC | 62% | 1 Depreciation and amortization 14,796 9,439 Amortization of operating lease right-of-use 29,388 41,386 Reinvested interests ( 83,346 ) ( 137,759 ) Increase in accounts receivable ( 277,116 ) ( 186,3… |
| PHARMA-SERV-INC | PHARMA-SERV-INC | 62% | 1 Depreciation and amortization 14,796 9,439 Amortization of operating lease right-of-use 29,388 41,386 Reinvested interests ( 83,346 ) ( 137,759 ) Increase in accounts receivable ( 277,116 ) ( 186,3… |
| ROMARK-BIOSCIENCES-LLC | ROMARK-BIOSCIENCES-LLC | 62% | . For the three months ended January 31, 2026 and 2025, net income and net earnings per common share (both basic and diluted) were approximately breakeven. 15 Table of Contents Liquidity and Capital … |
| ROMARK-GLOBAL-PHARMA-LLC-ROMARK-PROPERTIES-LLC | ROMARK-GLOBAL-PHARMA-LLC-ROMARK-PROPERTIES-LLC | 62% | . For the three months ended January 31, 2026 and 2025, net income and net earnings per common share (both basic and diluted) were approximately breakeven. 15 Table of Contents Liquidity and Capital … |
| ROMARK-HOLDINGS-LLC | ROMARK-HOLDINGS-LLC | 62% | . For the three months ended January 31, 2026 and 2025, net income and net earnings per common share (both basic and diluted) were approximately breakeven. 15 Table of Contents Liquidity and Capital … |
| SCIENZA-LABS-INC | SCIENZA-LABS-INC | 62% | r assets ( 21,595 ) ( 105,132 ) Decrease in liabilities ( 1,207,329 ) ( 326,662 ) NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES ( 566,701 ) 1,890,960 CASH FLOWS FROM INVESTING ACTIVITIES: Acquisit… |
| U-S-INVESTMENT-COMPANY | U-S-INVESTMENT-COMPANY | 62% | es (known as performance obligations) to its customers. Revenue for short term fixed fee contracts or “not to exceed” contracts is recognized similarly, except that certain milestones also must be re… |